| Name | Title | Contact Details |
|---|
Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.
Cetylite Industries Inc is a Pennsauken, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Commonwealth Biotechnologies is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We`re a company that takes on the toughest health challenges. But we do more than treat diseases—we aim to make a remarkable impact on people`s lives. We are AbbVie, a highly focused research-driven biopharmaceutical company. Our ~30,000 employees are scientists, researchers, communicators, manufacturing specialists and regulatory experts located around the globe. We come up with new approaches to addressing today`s health issues—from life-threatening illness to chronic conditions. We target specific difficult-to-cure diseases where we can leverage our core R&D expertise to advance science. We`re constantly working to create solutions that go beyond treating the illness to have a positive impact on patients` lives, on societies—and on science itself. At AbbVie, we see a future full of possibility, where health is in reach and patient lives are improved. See our employees, our science and our hope for tomorrow: Our purpose is profound, and our path is clear. We embrace the responsibility of making a remarkable impact on people`s lives through the innovative medicines and solutions we create together. This is driven by our compassion for people, commitment to innovation and inclusion, service to the community, and uncompromising integrity at the heart of everything we do. Operating as one AbbVie team, we care deeply for our patients, their families, our employees, and our communities. We strive to always do the right thing, pursuing the highest standards in quality, compliance, safety, and performance. In everything we do, we invest and innovate relentlessly to tackle unmet needs, creating new medicines and healthcare approaches for a healthier world. Globally, our employees embrace diverse backgrounds and perspectives and treat everyone equally, with dignity and respect, allowing us all to achieve our best. We proudly do our part to serve and support our communities and protect the environment, making a lasting impact that`s felt within healthcare and beyond. What we do isn`t easy, but we persevere because what we achieve inspires hope and transforms lives—every single day.